S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Penny Stock Shows Big Potential (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Penny Stock Shows Big Potential (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Penny Stock Shows Big Potential (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Penny Stock Shows Big Potential (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
NASDAQ:ONCS

OncoSec Medical - ONCS Stock Forecast, Price & News

$2.08
-0.18 (-7.96%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.04
$2.28
50-Day Range
$1.01
$2.89
52-Week Range
$0.74
$31.90
Volume
186,353 shs
Average Volume
6.15 million shs
Market Capitalization
$6.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ONCS stock logo

About OncoSec Medical (NASDAQ:ONCS) Stock

OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Ewing, NJ.

Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Stock News Headlines

Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
ONCS.OQ - | Stock Price & Latest News | Reuters
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
OncoSec Announces Pricing of $3.5 Million Public Offering
OncoSec provides updates on cancer programs in new filing
OncoSec Announces Reverse Stock Split
OncoSec Cuts Workforce, Prioritizes Pipeline
OncoSec Medical to Restructure, Cut Jobs
OncoSec Medical To Reduce Staff By About 45%
Robert Arch joins OncoSec Medical as CEO
OncoSec appoints new finance chief
See More Headlines
Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Company Calendar

Last Earnings
12/14/2021
Today
3/21/2023
Next Earnings (Estimated)
6/13/2023
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCS
Employees
54
Year Founded
2011

Profitability

Net Income
$-34,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.85) per share

Miscellaneous

Free Float
2,932,000
Market Cap
$6.18 million
Optionable
Not Optionable
Beta
1.76

Social Links


Key Executives

  • Robert H. Arch
    President, CEO & Non-Independent Director
  • George Chi
    Chief Financial Officer
  • David Canton
    Vice President-Research & Development
  • Sandra Aung
    Chief Clinical Development Officer & Senior VP
  • Bridget O'Keeffe
    Vice President-Clinical Development













ONCS Stock - Frequently Asked Questions

Should I buy or sell OncoSec Medical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings
or view top-rated stocks.

How have ONCS shares performed in 2023?

OncoSec Medical's stock was trading at $1.68 on January 1st, 2023. Since then, ONCS shares have increased by 23.8% and is now trading at $2.08.
View the best growth stocks for 2023 here
.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 443,400 shares, an increase of 1,853.3% from the February 13th total of 22,700 shares. Based on an average daily volume of 2,000,000 shares, the short-interest ratio is currently 0.2 days. Approximately 26.2% of the company's shares are sold short.
View OncoSec Medical's Short Interest
.

When is OncoSec Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 13th 2023.
View our ONCS earnings forecast
.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) posted its earnings results on Tuesday, December, 14th. The biotechnology company reported ($5.50) EPS for the quarter, topping the consensus estimate of ($8.14) by $2.64.

When did OncoSec Medical's stock split?

Shares of OncoSec Medical reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.81%), Two Sigma Investments LP (0.71%), Salzhauer Michael (0.70%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano and Yuhang Zhao.
View institutional ownership trends
.

How do I buy shares of OncoSec Medical?

Shares of ONCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $2.08.

How much money does OncoSec Medical make?

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $6.18 million. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($15.2865) on an earnings per share basis.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.

This page (NASDAQ:ONCS) was last updated on 3/21/2023 by MarketBeat.com Staff